Antidepressant Drugs: Indications and Guidelines for Use in Epilepsy
The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Abstract
Epilepsy patients who are diagnosed with clinical depression are often not treated with antidepressant drugs. There are a number of arguments for avoiding antidepressants in a person with active epilepsy; but there also are irrational worries. On the patient's side, there is often the fundamental problem that a diagnosis of depression cannot be accepted because psychiatric disorders are seen as even more stigmatizing than epilepsy. However, for the physician, who most often has little or no psychiatric training, there is often an inappropriate fear of using antidepressants because of proconvulsive properties and of kinetic and dynamic interactions with antiepileptic drugs (AEDs). Before prescribing antidepressants in a patient with epilepsy, it is necessary to consider etiologic factors, both psychological and biologic, which may be responsible for the development of a depressive reaction in the patient. The analysis of the AED regimen in terms of both positive and negative psychotropic effects of the prescribed drugs is particularly important. Mood-stabilizing properties of AED are used in psychiatry particularly in the treatment of and prophylaxis for affective disorders. Carbamazepine (CBZ) is used as an alternative to lithium in the long-term treatment of bipolar depression. Valproate (VPA) is particularly effective in the management of acute mania, but is also used as prophylaxis. Increasingly, AEDs of the new generation are being tested for a broad range of psychiatric indications. Controlled studies have confirmed that lamotrigine (LTG) is useful in the treatment of bipolar disorders (1). Gabapentin (GBP) has proved effective in specific anxiety disorders (2). Oxcarbazepine (OCBZ) is likely to have comparable mood-stabilizing properties with CBZ. There is limited experience with tiagabine (TGB) with mixed results, but based on positive observations, topiramate (TPM) is currently being tested intensively in affective disorders. There are, however, no controlled data as yet (3,4). Unfortunately there is a lack of systematic studies investigating the positive psychotropic effects of AEDs in epilepsy patients. Positive experiences with AEDs in psychiatry are not necessarily applicable to epileptology. Psychiatric disorders in epilepsy are different in their phenomenology and likely to have specific etiologies. Psychiatric treatment studies with AEDs focus on bipolar disorders, which are extremely rare in patients with epilepsy. Our knowledge of the negative psychiatric effects of conventional AEDs is largely empiric, based on anecdotal reports or small case series in the literature (Table 1). The exceptions are the barbiturates: several studies have shown that there is an increased risk of pharmacogenic depression in both adults and children treated with barbiturates (5–7). With respect to the so-called new AEDs, there is a considerable amount of data on negative psychotropic effects in epilepsy patients. However, the quality of this is limited because the source is drug trials that are designed to test antiseizure efficacy; and psychiatric side effects are not systematically documented. Further, these data do not allow the comparison of psychiatric risk profiles of new AEDs. Study designs are not homogeneous, and in particular, inclusion criteria vary between studies, and often patients with a psychiatric history are excluded, resulting in an underestimation of psychiatric complications. Finally, these data are not fully transparent to the interested epileptologist, at least not as soon as we would wish. Thus, there are many open questions with respect to psychiatric side effects of new AEDs (Table 2). Vigabatrin (VGB) was the first AED of the new generation to be licensed. There are two meta-analyses of placebo-controlled trials, which show that psychiatric complications occurred significantly more frequently in the VGB-treated patients than in the placebo groups. Levinson and Devinsky (8) and Ferrie et al. (9) analyzed 10 double-blind placebo-controlled studies. Psychiatric complications were differentiated by summarizing psychiatric complaints and psychopathologic symptoms into syndromatic diagnoses. Depressive episodes occurred in 12.1% of patients treated with VGB. The rate for depression in the placebo group was only 3.5%. From a detailed analysis of cases reported with serious psychiatric adverse events to the manufacturer of VGB in Europe, Thomas et al. (10) concluded that patients in whom psychotic episodes developed often had complete control of seizures with VGB (13 of 28 patients), consistent with the concept of alternative psychosis or forced normalization. In contrast to this, none of the patients with a depressive episode secondary to the introduction of VGB had become seizure free. This suggests that the depressive effects of VGB are not related to its antiepileptic properties. Two other new AEDs are associated with an increased rate of depressive disorders in controlled trials: TGB and
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Calabrese, J. R., Bowden, C. L., Sachs, G. S., Ascher, J. A., Monaghan, E., Rudd, G. D., & The Lamictal 602 Study Group (1999) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v60n0203 · Cited by 1,054
Cited by
Manford, M. (2017) · Journal of Neurology · doi:10.1007/s00415-017-8394-2 · Cited by 299
Ekinci, O., Titus, J. B., Rodopman, A. A., Berkem, M., & Trevathan, E. (2009) · Epilepsy & Behavior · doi:10.1016/j.yebeh.2008.08.015 · Cited by 186
“ciated with only a minimal seizure risk in adults [124].”
BackgroundPharmacological Augmentation in Unipolar Depression: A Guide to the Guidelines
Taylor, R. W., Marwood, L., Oprea, E., DeAngel, V., Mather, S., Valentini, B., Zahn, R., Young, A. H., & Cleare, A. J. (2020) · International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyaa033 · Cited by 76
“APA also cautioned that anticonvulsant compounds may negatively impact mood (Schmitz, 2002), as some, including barbiturates and potentially vigabatrin, have been associated with an increased risk of depression (Levinson and Devinsky, 1999) supported by a statement from the US Food and Drug…”
BackgroundKöster, M., Grohmann, R., Engel, R. R., Nitsche, M. A., Rüther, E., & Degner, D. (2013) · Psychopharmacology · doi:10.1007/s00213-013-3281-8 · Cited by 18
Metadata
- Authors
- Schmitz, B.
- Venue
- Epilepsia
- Publisher
- Wiley
- Published
- 2002-02
- Volume
- 43
- Issue
- s2
- Pages
- 14-18
- ISSN
- 0013-9580 (ISSN-L)
- 1528-1167
- OpenAlex
- W1983700851
- Cited by
- 36
- References
- 1
- FWCI
- 2.63
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Antidepressant Drugs: Indications and Guidelines for Use in Epilepsy. https://app.cochat.ai/papers/10.1046/j.1528-1157.2002.043s2014.x
- The paper
- Schmitz, B. (2002). Antidepressant Drugs: Indications and Guidelines for Use in Epilepsy. Epilepsia. https://doi.org/10.1046/j.1528-1157.2002.043s2014.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.